212 Pb-TCMC-Trastuzumab is under clinical development by Orano Med and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect 212 Pb-TCMC-Trastuzumab’s likelihood of approval (LoA) and phase transition for Breast Cancer took place on 04 Jun 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their 212 Pb-TCMC-Trastuzumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

212 Pb-TCMC-Trastuzumab overview

212 Pb-TCMC-trastuzumab is under development for the treatment of HER-2 expressing carcinomas including pancreatic neoplasms, ovarian, colon, endometrial, peritoneal, gastric and breast cancer. The drug candidate is administered intraperitoneally. It is the combination of trastuzumab with the radioisotope 212 Pb, through the use of a linker, TCMC. It is capable of releasing sufficient amounts of energy to destroy tumor cells.

Orano Med overview

Orano Med formerly AREVA Med, a subsidiary of Orano SA is a biotechnology company that develops innovative nuclear medicines to treat cancers. Its cancer pipeline products include 212Pb-TCMC-trastuzumab for treating intra-abdominal HER-2 expressing malignancy; 212Pb labeled peptide targeting neuroendocrine tumors (NETs); 212Pb labeled monoclonal antibodies against hematological malignancies; and 212Pb-conjugated anti-CD37 antibody to treat leukemia. Orano Med developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), a novel and potential research approach to nuclear medicine that facilitates the recognition and extermination of cancer cells while minimizing the damage to the healthy cells in the proximity. The company has collaborations with cancer research centers, universities, and other biotechnology companies. Orano Med is headquartered in Houston, Texas, the US.

Quick View 212 Pb-TCMC-Trastuzumab LOA Data

Report Segments
  • Innovator
Drug Name
  • 212 Pb-TCMC-Trastuzumab
Administration Pathway
  • Intraperitoneal
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Orano Med
  • Originator: Orano Med and F. Hoffmann-La Roche
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.